Semaglutide cancer and depression risks investigation

Concerns Ozempic ingredient may be related to thyroid cancer and suicide ideation draws attention of EMA Semaglutide, the active ingredient in hyped diabetes and weight loss drug, Ozempic and others, has been flagged as potentially increasing the risk of thyroid cancer and, separately, of causing suicidal thoughts. The dual scares come as supplies of Ozempic

This content is restricted to registered users only. If you have already registered on the AJP website please login below, Or you can Register for free.

Forgot Password?Why do I need to login & stay in?

Previous Webinar: Digital health update – responding to issues, incidents & patient queries
Next Mundipharma’s consumer health bought by iNova for $810m